What is Syndrome of Inappropriate Antidiuretic Hormone (SIADH)?
Syndrome of inappropriate antidiuretic hormone (SIADH) is a disorder of water balance in which the body releases too much antidiuretic hormone (ADH, also called vasopressin) despite normal or low plasma osmolality. ADH normally tells the kidneys to re‑absorb water, concentrating the urine. When ADH is inappropriately high, the kidneys retain water, diluting the blood (hyponatremia) while the urine remains inappropriately concentrated. The condition is not a disease itself but a physiological response to a wide variety of medical problems, medications, or central nervous system disturbances.1
Common Causes
More than one factor can trigger SIADH. The most frequent culprits fall into several categories:
- Malignancies – especially small‑cell lung carcinoma, pancreatic cancer, and lymphoma, which can produce ectopic ADH.2
- Central nervous system (CNS) disorders – stroke, subarachnoid hemorrhage, meningitis, encephalitis, traumatic brain injury, and postoperative states.3
- Pulmonary diseases – pneumonia, tuberculosis, asthma exacerbations, chronic obstructive pulmonary disease (COPD) flare, and acute respiratory distress syndrome (ARDS).4
- Medications – selective serotonin reuptake inhibitors (SSRIs), carbamazepine, cyclophosphamide, vincristine, vasopressin analogues, and certain chemotherapeutic agents.5
- Endocrine disorders – hypothyroidism and adrenal insufficiency can mimic or aggravate SIADH.6
- Post‑surgical states – especially after major thoracic or abdominal surgery, where stress hormones and pain can raise ADH secretion.
- Infections – viral (e.g., influenza, COVID‑19), bacterial sepsis, and HIV infection.7
- Hereditary or idiopathic SIADH – rare genetic mutations affecting ADH regulation or cases where no clear trigger is identified.
Associated Symptoms
Symptoms arise from the dilution of sodium in the bloodstream (hyponatremia) and the resulting cellular edema, particularly in the brain. The clinical picture can range from barely noticeable to life‑threatening.
- Headache
- Nausea and vomiting
- Loss of appetite
- Confusion, lethargy, or altered mental status
- Muscle cramps or weakness
- Seizures (especially when sodium < 120 mmol/L)
- Decreased coordination or gait instability
- Rapid, shallow breathing (in severe cases of cerebral edema)
Because the brain is most sensitive to rapid changes in sodium, patients often notice neurological changes before any obvious fluid overload (e.g., swollen ankles).8
When to See a Doctor
Prompt medical evaluation is essential if you experience any of the following:
- Persistent nausea, vomiting, or loss of appetite lasting more than 24 hours.
- Unexplained confusion, disorientation, or difficulty concentrating.
- Severe headache that does not improve with over‑the‑counter analgesics.
- Muscle cramps, weakness, or fainting spells.
- Any seizure activity, even a single event.
- Rapid weight gain (> 2 kg/5 lb in a day) without an obvious cause.
If you have a known risk factor (e.g., recent lung cancer diagnosis, recent surgery, or new psychiatric medication), contact your health‑care provider at the first sign of these symptoms.
Diagnosis
Diagnosing SIADH involves excluding other causes of hyponatremia and confirming the characteristic laboratory pattern.
Key Laboratory Findings
- Serum sodium: typically < 135 mmol/L, often 120–130 mmol/L in symptomatic patients.
- Serum osmolality: low (< 275 mOsm/kg).
- Urine osmolality: inappropriately high (> 100 mOsm/kg) despite low serum osmolality.
- Urine sodium: usually > 40 mmol/L, reflecting continued renal sodium loss.
- Serum uric acid and BUN: often low because of dilution.
Exclusion of Other Conditions
Doctors will rule out:
- Hypothyroidism – measured by TSH and free T4.
- Adrenal insufficiency – cortisol and ACTH assays.
- Renal failure – creatinine, eGFR.
- Volume depletion – clinical exam and orthostatic vitals.
Imaging & Specialized Tests
- Chest X‑ray or CT scan to look for lung tumors or infection.
- Brain MRI/CT if neurologic symptoms suggest a CNS cause.
- Medication review – identifying drugs known to provoke ADH release.
Guidelines from the American Society of Nephrology and the European Clinical Practice Guideline recommend using the European Society of Endocrinology (ESE) 2013 criteria for a definitive SIADH diagnosis.9
Treatment Options
Treatment goals are to safely raise serum sodium, address the underlying cause, and prevent re‑accumulation.
1. Manage the Underlying Trigger
- Oncologic therapy for ectopic ADH‑secreting tumors.
- Antibiotics or antivirals for infections.
- Discontinuation or substitution of offending medications (e.g., switch SSRIs to an alternative).
- Surgical evacuation of intracranial lesions or control of intracranial pressure.
2. Fluid Restriction
The cornerstone of initial therapy is restricting free water intake to 800–1000 mL per day. Most patients respond within 24–48 hours. Close monitoring is essential because overly rapid correction can cause osmotic demyelination syndrome (ODS).10
3. Pharmacologic Options
- Loop diuretics (e.g., furosemide) – increase free water excretion when combined with fluid restriction.
- Vaptans (tolvaptan, conivaptan) – selective vasopressin‑2 receptor antagonists that cause aquaresis (free‑water loss) without electrolyte loss. Usually reserved for moderate‑to‑severe cases or when fluid restriction fails.11
- Hypertonic saline (3 % NaCl) – administered intravenously for severe or symptomatic hyponatremia (Na < 120 mmol/L, seizures, coma). Must be infused slowly (≤ 8‑10 mmol/L per 24 h) to avoid ODS.
- Urea – oral or nasogastric urea can increase free water clearance; used in some European protocols.
4. Monitoring
Serum sodium should be checked every 2‑4 hours during acute correction, then at least daily until stable. Electrolytes, urine output, and neurological status must be documented.
5. Home & Lifestyle Measures (after acute phase)
- Adhere to prescribed fluid limits; use a measured water bottle.
- Limit high‑water‑content foods (soups, fruits) if advised by the clinician.
- Maintain a balanced diet rich in protein and modest sodium (as directed).
- Keep a symptom diary—note headaches, dizziness, or changes in mental status.
Prevention Tips
While many cases are unavoidable, certain steps can reduce risk:
- Medication review – ask your physician to assess the necessity of drugs known to cause SIADH, especially when starting new psychiatric or chemotherapeutic agents.
- Prompt treatment of infections – early antibiotics for pneumonia or antiviral therapy for influenza/COVID‑19 can limit pulmonary triggers.
- Regular monitoring in high‑risk patients – oncology patients, postoperative individuals, and those with chronic CNS disease should have routine serum sodium checks.
- Stay hydrated wisely – during illnesses with fever or vomiting, replace losses with electrolyte solutions (e.g., oral rehydration salts) rather than plain water.
- Educate caregivers – family members of patients with known SIADH should know fluid limits and warning signs.
Emergency Warning Signs
- Severe headache or sudden worsening of confusion.
- Seizure activity or new onset of tremors.
- Vomiting that prevents keeping any fluids down.
- Rapid decline in consciousness (drowsiness, inability to arouse).
- Focal neurological deficits (weakness on one side, slurred speech).
- Serum sodium < 120 mmol/L confirmed by a recent lab test.
If any of these occur, seek emergency medical care immediately (call 911 or go to the nearest emergency department).
Key Take‑aways
SIADH is a potentially serious but treatable cause of hyponatremia. Early recognition, careful fluid management, and treatment of the underlying trigger are essential to prevent complications such as seizures or permanent brain injury. Patients and caregivers should be vigilant for neurologic changes and know when to call for urgent care.
References:
1. Mayo Clinic. “Syndrome of inappropriate antidiuretic hormone (SIADH).” 2023.
2. UpToDate. “Ectopic ADH production and SIADH in malignancy.” 2024.
3. National Institute of Neurological Disorders and Stroke. “Hyponatremia.” 2022.
4. CDC. “Pneumonia and hyponatremia.” 2021.
5. FDA Drug Safety Communications. “ADH‑related hyponatremia with SSRIs and antiepileptics.” 2023.
6. Cleveland Clinic. “Hypothyroidism and hyponatremia.” 2022.
7. WHO. “COVID‑19 clinical management guidance (2024 update).”
8. NIH. “Hyponatremia: Clinical manifestations and treatment.” 2023.
9. European Society of Endocrinology. “Guidelines for the diagnosis of SIADH.” 2013.
10. American Society of Nephrology. “Management of hyponatremia.” 2022.
11. JAMA. “Vaptans for SIADH: A systematic review.” 2023.